Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral Therapy
Open Access
- 24 January 2006
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (3) , e52
- https://doi.org/10.1371/journal.pmed.0030052
Abstract
Protease inhibitors (PIs) are associated with hypertriglyceridemia and atherogenic dyslipidemia. Identifying HIV-1-infected individuals who are at increased risk of PI-related dyslipidemia will facilitate therapeutic choices that maintain viral suppression while reducing risk of atherosclerotic diseases. Apolipoprotein C-III (apoC-III) gene variants, which vary by race/ethnicity, have been associated with a lipid profile that resembles PI-induced dyslipidemia. However, the association of race/ethnicity, or candidate gene effects across race/ethnicity, with plasma lipid levels in HIV-1-infected individuals, has not been reported. A cross-sectional analysis of race/ethnicity, apoC-III/apoA-I genotypes, and PI exposure on plasma lipids was performed in AIDS Clinical Trial Group studies (n = 626). Race/ethnicity was a highly significant predictor of plasma lipids in fully adjusted models. Furthermore, in stratified analyses, the effect of PI exposure appeared to differ across race/ethnicity. Black/non-Hispanic, compared with White/non-Hispanics and Hispanics, had lower plasma triglyceride (TG) levels overall, but the greatest increase in TG levels when exposed to PIs. In Hispanics, current PI antiretroviral therapy (ART) exposure was associated with a significantly smaller increase in TGs among patients with variant alleles at apoC-III-482, −455, and Intron 1, or at a composite apoC-III genotype, compared with patients with the wild-type genotypes. In the first pharmacogenetic study of its kind in HIV-1 disease, we found race/ethnic-specific differences in plasma lipid levels on ART, as well as differences in the influence of the apoC-III gene on the development of PI-related hypertriglyceridemia. Given the multi-ethnic distribution of HIV-1 infection, our findings underscore the need for future studies of metabolic and cardiovascular complications of ART that specifically account for racial/ethnic heterogeneity, particularly when assessing candidate gene effects.Keywords
This publication has 66 references indexed in Scilit:
- Modeling the Influence ofAPOC3, APOE,andTNFPolymorphisms on the Risk of Antiretroviral Therapy–Associated Lipid DisordersThe Journal of Infectious Diseases, 2005
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLoS Medicine, 2004
- The effects of scale: variation in the APOA1/C3/A4/A5 gene clusterHuman Genetics, 2004
- Interaction between the APOC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteinsAtherosclerosis, 2003
- A Combinatorial Partitioning Method to Identify Multilocus Genotypic Partitions That Predict Quantitative Trait VariationGenome Research, 2001
- Population frequency distribution of non–high-density lipoprotein cholesterol (third national health and nutrition examination survey [NHANES iii], 1988–1994)The American Journal of Cardiology, 2000
- Intestinal transcription and synthesis of apolipoprotein AI is regulated by five natural polymorphisms upstream of the apolipoprotein CIII gene.Journal of Clinical Investigation, 1997
- Variation at the lipoprotein lipase and apolipoprotein AI-CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: Interaction between genotype, gender, and smoking statusGenetic Epidemiology, 1997
- Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school childrenHuman Genetics, 1996
- Polymorphic Markers in Apolipoprotein C-III Gene Flanking Regions and HypertriglyceridemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1996